Thymogen peptide is a lyophilized vial of the dipeptide Glu-Trp, written EW, the thymus-directed compound in the Khavinson bioregulator range. It is one of only two dipeptides in the family and the only one carrying an aromatic residue.
Specification Table
Thymogen calculated chemical and handling data
| Property |
Value |
| Compound |
Thymogen |
| Sequence designation |
EW |
| Amino acid sequence |
Glutamate-Tryptophan |
| Residue count |
2 |
| Molecular weight, calculated |
333.4 g/mol, computed from standard residue masses plus water. Not a cited literature value; confirm against the lot certificate |
| Net charge at neutral pH |
Negative, from the glutamate |
| Oxidation-prone residues |
Tryptophan at position 2 |
| Chromophore |
Tryptophan, giving strong 280 nm absorbance |
| Distinct from |
Thymalin, a peptide mixture rather than a defined sequence, and Thymosin alpha-1, a 28-residue peptide |
| Compound class |
Short peptide bioregulator, cytogen subclass |
| Cytogen versus cytomax |
Cytogen. A laboratory-synthesised defined sequence, not a tissue extract |
| Source tissue of the parent fraction |
Thymus tissue |
| Originating programme |
St Petersburg Institute of Bioregulation and Gerontology |
| Programme lead |
Vladimir Khavinson |
| Proposed mechanism in the literature |
Sequence-specific interaction with DNA, modulating tissue-associated gene expression |
| Mechanism status |
Hypothesis. Not independently established outside the originating programme |
| Receptor |
None identified |
| Appearance |
White lyophilized powder |
| Purity |
Per lot-specific certificate of analysis |
| Solubility |
Water soluble |
| Storage, lyophilized |
2-8°C or -20°C, protected from light and moisture |
| Regulatory status |
No approved human or veterinary formulation in any jurisdiction |
What Is Thymogen Peptide and What Is It Not?
Thymogen peptide is one of three thymic preparations circulating under overlapping descriptions and confusing them is the commonest error around this compound.
Thymogen is the dipeptide Glu-Trp, a single defined sequence of two residues, and it is a cytogen: laboratory-synthesised and fully characterisable by routine analysis.
Thymalin is a peptide mixture extracted from thymus tissue, so it is a cytomax: a fraction rather than a molecule. No mass spectrum characterises it completely, because there is no single mass to measure.
Thymosin alpha-1 is a 28-residue peptide from an entirely different research lineage carrying its own substantial independent literature, and it shares a tissue association with the other two and nothing else.
Literature about any one of the three does not transfer to the others. A mass near 333 confirms Thymogen, and the absence of a single defined mass confirms Thymalin.
Secondary sources move between the three without flagging the switch, which is why checking the methods section of any citation is worth the minute it takes.
Why Is the Tryptophan Significant Here?
Thymogen peptide shares with Pancragen the distinction of carrying tryptophan, and in a two-residue peptide that single aromatic residue is half the molecule.
Tryptophan oxidises readily, adding 16 daltons, and it is photosensitive under ultraviolet and more slowly under ambient light, which together make Thymogen and Pancragen the two least stable compounds in this family.
Every other bioregulator in this catalogue lacks tryptophan, methionine and cysteine entirely, which is why they tolerate handling that would degrade an ordinary peptide. These two do not share that immunity.
The useful consequence is analytical, because tryptophan gives strong absorbance at 280 nanometres and concentration determination therefore requires no standard curve once the extinction coefficient is known.
In a dipeptide that signal is proportionally enormous, because one of two residues is the chromophore. Thymogen is the easiest compound in this family to quantify accurately.
A plus-16 satellite on the mass spectrum is the direct oxidation check, and with one oxidisable residue in two the interpretation is unambiguous.
What Does a Two-Residue Bioregulator Require of the Hypothesis?
Thymogen peptide and Vilon are the two shortest compounds in the range, and they set the tightest constraints on the proposed mechanism.
Two residues give one peptide bond, essentially no conformational preference, and a surface area smaller than most small-molecule drugs. That is not much for a recognition event to work with.
The programme hypothesis proposes sequence-specific interaction with DNA, modulating transcription of tissue-associated genes, and for two residues that proposal is considerably more demanding than it is for a tetrapeptide.
Sequence-specific DNA recognition normally requires reading several base pairs across a folded recognition surface. A two-residue ligand offers minimal information content to do it with.
Thymogen adds a wrinkle Vilon does not. Tryptophan is the classic intercalating residue in protein-DNA and small-molecule-DNA interactions, so if any bioregulator has a plausible structural route to DNA association, this is the one.
That makes Thymogen the most informative single test case in the family. A binding measurement here would constrain the hypothesis more sharply than the same measurement on any other member.
What Is a Thymus Bioregulator?
The organ term is searched more than Thymogen peptide is, and it names the premise behind the whole programme rather than a pharmacological class.
The St Petersburg group fractionated organ extracts on the idea that each contains short peptides carrying tissue-specific regulatory information, and named each resulting compound after its source organ.
Thymogen came from thymus tissue, and so did Thymalin, which is why the two names are so easily confused despite describing entirely different kinds of preparation.
The thymus association carries an implication about where the compound acts, and that implication is inherited from the fractionation methodology rather than demonstrated by tissue-distribution work.
No tissue-distribution study across this family appears in the published record. That is the clearest testable gap here.
Until it exists, organ names should be read as programme labels describing where a compound came from rather than established statements about where it goes.
What Thymogen Dosage Figures Are Published?
The figures below are amounts used in published studies, in the species those studies used, with the family caveats attached.
Published rodent studies sit in the microgram per kilogram band by parenteral routes, which matches the rest of the Khavinson range and sits far below where most peptides in this catalogue are studied.
The Russian clinical record describes ten to twenty day courses at tens to low hundreds of micrograms, structured as discrete courses rather than open-ended exposure.
That course structure recurs across the family and differs from the continuous-exposure designs common elsewhere, so anyone reproducing published work should match the schedule as well as the quantity.
No receptor affinity is known, so no concentration can be justified from first principles and wide ranging is a requirement rather than good practice.
Allometric scaling through body surface area is required for any cross-species comparison. Body weight arithmetic alone overestimates substantially.
How Should Thymogen Peptide Be Stored and Divided?
Light protection first, because the tryptophan makes this one of only two compounds in the family that genuinely needs it.
Hold lyophilized Thymogen peptide cold, sealed and dark, in an opaque container or its original packaging.
Protect it during weighing and reconstitution as well as in storage. A tryptophan-containing peptide left on an open bench under fluorescent light is degrading while it sits there.
Reconstituted solution goes at 2 to 8 degrees in the dark, aliquoted before freezing, because unlike its tryptophan-free relatives this compound will not tolerate casual handling indefinitely.
Check concentration spectrophotometrically at 280 nanometres before critical work rather than trusting the nominal figure, and that option exists here and on almost nothing else in this range.
Record lot, counterion, net peptide content, diluent, volume, measured concentration, date, and any light exposure during handling.
What Should Thymogen For Sale Documentation Show?
Thymogen peptide is the simplest analysis in this catalogue, and the tryptophan makes one check easier and one necessary.
Mass against roughly 333.4 for the free dipeptide. Ask for the oxidised fraction quantified rather than merely absent, since absence usually means nobody measured it.
Concentration by 280 nanometre absorbance, which is available here and on almost nothing else in this family. A supplier who has not used it has not tried very hard.
Purity by reversed-phase chromatography, noting that the tryptophan gives considerably more retention than a polar dipeptide would have, so the method differs from what Vilon or Chonluten need.
Counterion identity, reported next to net peptide content. At 333.4 daltons a trifluoroacetate at 114 is over 25 percent of the associated mass, second only to Vilon in this family.
Sequence stated explicitly as Glu-Trp, and the product named unambiguously against Thymalin and Thymosin alpha-1.
A last note on sourcing across the thymic preparations. Because three different products carry overlapping names and overlapping tissue associations, a supplier shipping the wrong one produces something that looks plausible on the label.
A mass spectrum settles it immediately. Near 333 is Thymogen, near 3100 is Thymosin alpha-1, and a spectrum with no single dominant species is Thymalin.
Asking for the measured mass rather than accepting the trade name is worth more here than almost anywhere else in the catalogue, because all three are sold into overlapping markets by overlapping suppliers.
That check takes one line on a certificate and it removes the entire category of error.
One further point on the naming. Thymogen is occasionally written as Glutamyl-Tryptophan or as Thymogen dipeptide in older sources.
Both refer to the same molecule, and searching under the sequence rather than any trade name is the only reliable way to surface the full literature on a compound whose names have moved this much.
That habit matters more here than for most compounds, because the thymic preparations have accumulated more overlapping nomenclature than anything else in the Khavinson range.
For a compound sold under three overlapping names, that single check is the cheapest quality control available to a buyer.
It costs nothing.
A supplier who cannot produce a measured mass for a two-residue peptide, the simplest analysis anyone in this catalogue could be asked to perform on the smallest molecule in the entire Khavinson range, has told you everything you need to know about how they handle the rest of their inventory.
Ask once, early.
Published Literature
References verified against the publisher record. As across this family, the literature originates almost entirely from one research programme.
- Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, Basel; 2005.
- Khavinson VK. Neuroendocrinology Letters. 2002;23(Suppl 3):11-144.
- Anisimov VN, Khavinson VK. Critical Reviews in Oncology/Hematology. 2010;74(1):46-66.
- Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Biochemistry (Moscow). 2011;76(11):1210-1219.
- Khavinson VK, Solovyov AY, Zhilinsky DV, Shataeva LK, Bandaletova TY. Bulletin of Experimental Biology and Medicine. 2012;153(4):500-505.
Frequently Asked Questions
What is Thymogen peptide?
A lyophilized vial of the dipeptide Glu-Trp, written EW, the thymus-directed compound in the Khavinson bioregulator range. One of only two dipeptides in the family. Laboratory research use only.
How is it different from Thymalin?
Thymogen is a single defined two-residue sequence. Thymalin is a peptide mixture extracted from thymus tissue, so it is a fraction rather than a molecule and no mass spectrum can characterise it completely.
How is it different from Thymosin alpha-1?
Thymosin alpha-1 is a 28-residue peptide from an entirely different research lineage with its own substantial independent literature. It shares a tissue association with the other two and nothing else.
How can they be told apart on paper?
By mass. A figure near 333 confirms Thymogen, and the absence of a single defined mass confirms Thymalin. A figure near 3100 confirms Thymosin alpha-1, and literature about one does not transfer to the others.
Why does the tryptophan matter?
Because in a two-residue peptide it is half the molecule. It oxidises readily and is photosensitive, making Thymogen and Pancragen the two least stable compounds in this family.
What is the analytical upside?
Strong 280 nanometre absorbance, proportionally enormous because one of two residues is the chromophore. Thymogen is the easiest compound in this family to quantify accurately, and most of the others have no chromophore at all.
What does a dipeptide demand of the mechanism?
A great deal. Sequence-specific DNA recognition normally requires reading several base pairs across a folded surface, and two residues offer minimal information content to do it with.
Does Thymogen have a structural advantage there?
Possibly. Tryptophan is the classic intercalating residue in protein-DNA and small-molecule-DNA interactions, so if any bioregulator has a plausible structural route to DNA association, this is the one.
What would that make it useful for?
The most informative single test case in the family. A direct binding measurement on Thymogen would constrain the hypothesis more sharply than the same measurement on any other member.
What dosage figures are published?
Published rodent studies sit in the microgram per kilogram band by parenteral routes. The Russian clinical record describes ten to twenty day courses at tens to low hundreds of micrograms.
How large is the counterion correction?
At roughly 333.4 daltons a single trifluoroacetate at 114 is over 25 percent of the associated mass, second only to Vilon in this family. Net peptide content is the figure to calculate from.
Compliance Statement
Thymogen peptide is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, its proposed mechanism has not been independently established, and it should not be confused with Thymalin or Thymosin alpha-1, which are different substances. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
19 reviews for Thymogen Peptide 20mg